WINNIPEG, MB, Feb. 22,
2022 /CNW/ - Medicure Inc. ("Medicure" or the
"Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the
development and commercialization of pharmaceuticals and healthcare
products for patients and prescribers in the United States market, is pleased to
announce the integration of its subsidiary, Marley
Drug® pharmacy, as the sole mail-order pharmacy for
RxSpark™, the next generation in pharmacy discount programs.
Described as a much-needed disruptor in the health and pharmacy
space, technology company RxSpark addresses an urgent need with its
proprietary prescription drug savings program through
www.rxspark.com. Poor-coverage or lack of health insurance,
exacerbated by the economic impact of the COVID-19 pandemic, has
placed prescription medication beyond the reach of many Americans.
Additionally, the COVID-19 pandemic has accelerated changes to the
healthcare system unlike any other recent event, with increased
consumer demand for online services such as telehealth, remote
patient monitoring and home delivery of medications. For its
customers, the RxSpark platform offers a powerful search function
and an improved drug results capacity which makes it easier to find
the best discounted prices for medications in nearby pharmacies
throughout the U.S.
The integration of Marley Drug as the sole mail-order pharmacy
for the RxSpark platform now allows consumers using the platform to
receive medication directly to their door. The Marley Drug home
delivery service will be available to all consumers regardless of
where they may live in the U.S., as Marley Drug is licensed to
provide medication in all 50 states and most territories. Apart
from the typical 30- and 90-day fill of medication, Marley Drug
also offer customers the ability to acquire extended supply fills
of 6- and 12-months. For chronic care medication, 6- and 12-month
quantities could increase patient adherence and lead to better
management of medical conditions. Additional benefits include fewer
pharmacy visits, less frequent refills and overall reduced cost.
Marley Drug will provide well over 100 chronic care medications at
$37 for 6-months and $70-for 12 months with free delivery anywhere in
the United States and some
territories.
Says Albert D. Friesen, PhD,
Chief Executive Officer of Medicure and Chair of its Board of
Directors - "We are pleased to partner with RxSpark and to serve as
the sole mail-order pharmacy on the platform. Many Americans do not
realize that prescription drug pricing can significantly vary from
one pharmacy to another, and even from day to day. However, having
Marley Drug as a consistent option for affordable medication that
is accessible by all Americans regardless of where they may live,
using the RxSpark platform, will provide a reasonable option for
medication disparities. This is another step forward to adapt to
the rapidly changing health care landscape which places the
consumer first, and it is also part of our broader growth strategy,
which recently included launching the Marley Drug Pharmacy
e-commerce platform – www.marleydrug.com."
"In light of seismic changes to the health ecospace and the
shift to online services, we are excited to be partnering with
Marley Drug to offer mail order medications to our members across
the whole of the U.S. Our goal has always been to improve access to
affordable prescription medications and thereby encourage adherence
to treatment plans and contribute to a healthier America.
Partnering with Marley Drug expands this offering, adding an
affordable mail order option to our prescription savings program,"
says John Casson, CEO and Founder of
RxSpark.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development
and commercialization of innovative and affordable therapeutics for
the U.S. market. Medicure's sales force markets to physicians and
other healthcare professionals and now with E-Commerce integration,
will be offering patients and providers direct online ordering and
home delivery. Our vision is to become a leading pharmaceutical
company within the U.S, offering a growing portfolio of products
that improve patients' lives. The present focus of the Company is
the marketing and distribution of AGGRASTAT® (tirofiban
hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in
the United States, where they are
sold through the Company's U.S. subsidiary, Medicure Pharma Inc.
Medicure also operates Marley Drug®, Inc. ("Marley Drug"), a
pharmacy located in North Carolina
that offers an Extended Supply drug program serving all 50 states,
Washington D.C. and most
territories, including Puerto
Rico. Marley Drug is committed to improving the health
status of its patients and the communities they serve while
reducing overall health care costs for employers and other health
care consumers. For more information visit www.marleydrug.com. To
learn more about The Extended Supply Generic Drug Program call
800.286.6781 or e-mail info@marleydrug.com. For more information on
Medicure please visit https://www.medicure.com/. For additional
information about AGGRASTAT®, refer to the full Prescribing
Information. For additional information about ZYPITAMAG®, refer to
the full Prescribing Information.
To be added to Medicure's e-mail list, please
visit: https://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this press
release that are not statements of historical fact, including,
without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates",
"intends", "expects" and similar expressions, may constitute
"forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking
information and forward-looking statements are hereinafter
collectively referred to as "forward-looking statements").
Forward-looking statements, include estimates, analysis and
opinions of management of the Company made in light of its
experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
results, including future revenue from the E-Commerce platform,
expected future growth in revenues, stage of development,
additional capital requirements, risks associated with the
completion and timing of clinical trials and obtaining regulatory
approval to market the Company's products, the ability to protect
its intellectual property, dependence upon collaborative partners,
changes in government regulation or regulatory approval processes,
and rapid technological change in the industry. Such statements are
based on a number of assumptions which may prove to be incorrect,
including, but not limited to, assumptions about: general business
and economic conditions; the impact of changes in Canadian-US
dollar and other foreign exchange rates on the Company's revenues,
costs and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of
current and future clinical trials; the uncertainties associated
with the acceptance and demand for new products and market
competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31, 2020.
View original
content:https://www.prnewswire.com/news-releases/medicures-subsidiary---marley-drug-to-partner-with-rxspark-the-next-generation-in-pharmacy-discount-programs-to-be-its-sole-mail-order-pharmacy-301487410.html
SOURCE Medicure Inc.
